A novel subset of hepatocytes is simultaneously gluconeogenic and *de novo* lipogenic in the fed state and is naturally insulin resistant

Junichi Okada[1], Austin Landgraf[2], Maxwell Horton[2,3], Yunping Qiu[1,4], Alus M. Xiaoli[1,5], Roberto Ribas[6], Li Liu[1], Sofia V. Krylova[2], Victor L. Schuster[7], Fajun Yang[1,5], Takeshi Saito[8], Ramon C. Sun[6,9,10], Meredith Hawkins[1], Gary J Schwartz[1,11,12], Carolina Eliscovich[5,13], Kosaku Shinoda[1,2], Irwin J. Kurland[1,4] and Jeffrey E. Pessin[1,2]

[1]Departments of Medicine (Division of Endocrinology), [2]Molecular Pharmacology, [3]Biochemistry, [5]Developmental and Molecular Biology, [7]Medicine (Division of Nephrology), [11]Neuroscience, [12]Psychiatry and Behavioral Sciences and [13]Medicine (Hepatology). [4]Stable Isotope and Metabolomics Core Facility, New York Regional Diabetes Research Center. Fleischer Institute for Diabetes and Metabolism, The Albert Einstein College of Medicine, Bronx, NY 10461

[6]Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, FL 32610

[8]Department of Medicine, Division of Gastrointestinal and Liver Diseases, Immunology & Immune Therapeutics, and Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033

[9]Center for Advanced Spatial Biomolecule Research, University of Florida, Gainesville, FL 32610

[10]Evelyn F. and William L. McKnight Brain Institute, University of Florida, Gainesville, FL 32610

Please address correspondences to:

Junichi Okada
Department of Medicine (Division of Endocrinology)
The Albert Einstein College of Medicine
369 Price Center, 1301 Morris Park Avenue
Bronx, NY 10461
Email: junichi.okada@einsteinmed.edu

ABSTRACT

It is generally accepted that hepatic gluconeogenesis, the synthesis of glucose

from non-carbohydrate substrates is active in the fasted state and inactive in the fed

state. In contrast, *de novo* lipogenesis is active in the fed state and is inactive in the

fasted state. Here, we used targeted single cell RNA-seq, HCR RNA-FISH, and

PrimeFlow in normal physiological mouse liver, and identified a subpopulation of

periportal hepatocytes that simultaneously co-express both gluconeogenic and lipogenic

genes in the fed state. Euglycemic-hyperinsulinemic clamps further demonstrated that

this novel hepatocyte subpopulation is naturally insulin resistant. Spatial metabolic

imaging coupled with stable isotope tracing analyses revealed individual hepatocytes

that simultaneously undergo both gluconeogenesis and *de novo* lipogenesis. These

dual-positive hepatocytes were also present in human hepatocytes from humanized

mouse livers. Moreover, the number of dual-positive hepatocytes increased in high-fat

diet-fed mice, suggesting a paradigm shift in our understanding of how the liver

becomes insulin resistant.

INTRODUCTION

The mammalian liver is composed of parenchymal (hepatocytes) and non-

parenchymal (endothelial, Kupffer, cholangiocytes, stellate) cells organized into

repetitive hexagonal arrays termed lobules[1,2]. Within each lobule the hepatocytes are

distributed from the portal triad (portal vein, hepatic artery, bile duct) at the six vertices

and the central vein located at the centroid of the hexagon. The hepatocytes aligned

within a lobule display functionally distinct metabolic properties and are generally

divided into three zones: the periportal hepatocytes (zone 1), midlobular hepatocytes

(zone 2) and the pericentral hepatocytes (zone 3), with emerging single-cell studies

indicating that hepatic zonation exists along a more continuous and finely partitioned

spectrum[3,4]. The pericentral hepatocytes display higher rates of glycolysis, bile acid and

glutamine biosynthesis[1,2]. The periportal hepatocytes are primarily responsible for beta-

oxidation and urea oxidation and in particular, gluconeogenesis[1,2]. However,

gluconeogenesis is a dynamic process that is regulated by numerous hormonal, neural

and metabolic inputs. During early states of fasting *in vivo*, we found that periportal

hepatocytes are initially responsible for gluconeogenesis, but as fasting duration

increased, the mid-zone and then pericentral hepatocytes underwent increased

gluconeogenic gene expression, protein levels and ultimately gluconeogenic activity that

approached that of the periportal hepatocytes[5]. In contrast, lipogenic gene expression

that is high in the fed state is rapidly downregulated to essentially undetectable levels

during the initial time frame of fasting induction. These data demonstrate the remarkable

plasticity of hepatocyte gluconeogenic gene expression and gluconeogenic activity

across the liver lobule depending upon organismal nutrient state.

While it is generally accepted that *de novo* lipogenesis is activated in the fed state

whereas gluconeogenesis and hepatic glucose output are activated in the fasted state,

several studies observed a measurable rate of gluconeogenesis and hepatic glucose

production in the fed state, despite the availability of dietary glucose[6,7]. Although not

thoroughly investigated, the molecular and cellular bases for the basal rate of hepatic

gluconeogenesis and hepatic glucose output was generally thought to represent

glucose production for the indirect pathway of glycogen synthesis[8-11].

In this study, we used a variety of single cell technologies to confirm the presence of

basal liver gluconeogenic activity transcriptionally and functionally in the fed state that

results in hepatic glucose release. Importantly, our data revealed that this basal

gluconeogenesis results from a subset of unique hepatocytes that simultaneously

display expression of both *de novo* lipogenic and gluconeogenic genes exclusively

localized to the periportal region. Spatial metabolomic imaging further confirmed that

this subset of periportal hepatocytes is capable of simultaneously undergoing both

gluconeogenesis and *de novo* lipogenesis, and have high rates of ATP turnover,

consistent with the energetic need to sustain these dual processes. Furthermore,

euglycemic-hyperinsulinemic clamps and PrimeFlow analyses suggested that these

hepatocytes are resistant to insulin suppression of gluconeogenic gene expression,

demonstrating natural insulin resistance under normal physiological conditions.

Moreover, the number of these naturally insulin-resistant hepatocytes is increased by

high-fat diet feeding.

RESULTS

Gluconeogenic genes are transcribed in hepatocytes in the fed state

To investigate the regulation of liver gene expression in the normal physiological

transitions between fed and fasted states, we used a previously established protocol in

which mice rapidly consume food and fill their stomachs to create a relatively uniform

fed state, and following food removal, facilitate a uniform transition into the fasted

state[5,12]. We first confirmed our previous findings that lipogenic gene *Fasn* mRNA is

highly expressed in the fed state of total primary isolated hepatocytes and nearly

completely suppressed in the fasted state (Fig. 1A). In contrast to lipogenic gene

mRNA, the gluconeogenic gene *Pck1,* was highly expressed in the fasted state, yet

surprisingly there was a low but readily detectable mRNA in the fed state as well (Fig.

1B). There were no significant effects of fasting/feeding on the expression of

constitutively expressed gene albumin (*Alb*) mRNA (Fig. 1C). To determine if the

observed feeding state changes in mRNA levels were due to a transcriptional process,

we examined the transcriptional activation of lipogenic and gluconeogenic genes by

performing DNA-dependent RNA polymerase II (RNAPII) ChIP-seq to assess RNAPII

gene occupancy in total primary isolated hepatocytes. As expected, RNAPII occupancy

was relatively high across the gene body of *Fasn* in the fed state with very low binding

in the fasted state (Fig. 1D). RNAPII occupancy on other lipogenic genes *Acly* and

Elovl6, displayed a similar pattern (Fig. S1A and S1B). Both *Fasn* and *Acly* displayed a

peak of RNAPII at the transcription start site indicative of proximal promoter pausing[13].

In contrast, the gluconeogenic genes *Pck1* and *G6pc* showed the opposite trend with

higher RNAPII occupancy in the fasted state. Although both *Pck1* (Fig. 1E) and *G6pc*

(Fig. S1C) displayed strong gene occupancy by RNAPII in their active (fasted) state, we

also observed RNAPII gene occupancy in the inactive fed state. In addition, there was

no evidence of proximal promoter pausing for the gluconeogenic genes. In contrast,

there were no changes in RNAPII occupancy for *Alb* (a constitutive hepatocyte gene,

Fig. 1F). As a control, the *Ins1* gene, which is not expressed in hepatocytes, showed

virtually no RNAPII occupancy in either the fed or fasted state (Fig. 1G).

The apparent transcription of gluconeogenic genes in the fed state could occur in all

hepatocytes or be restricted to a subset of hepatocytes. To explore these possibilities,

we isolated pericentral and periportal hepatocytes from fed and 16 h fasted mice using

a digitonin ablation method that we modified for application in mice[5,14,15]. The isolated

pericentral (PC) and periportal (PP) hepatocytes were then subjected to RNAPII ChIP-

seq analyses. To confirm the relative purity of separation we examined the mRNA

expression levels of *Cyp2e1*, an established PC hepatocyte marker, and *Cyp2f2*, an

established PP marker[3,5,16]. As shown in Figure S2A there was a ~ 6 to 9-fold

enrichment of *Cyp2e1* in the PC hepatocytes and an ~ 4 to 6-fold enrichment of *Cyp2f2*

in the PP hepatocytes (Fig. S2B).

RNAPII ChIP-seq demonstrated that *Fasn* gene was transcriptionally active in both

the PC and PP hepatocytes in the fed state, although somewhat greater in the PP

hepatocytes (Fig. S2C). The *Fasn* gene occupancy of RNAPII in both PC and PP

hepatocytes is consistent with the mRNA expression of lipogenic genes levels across

the liver lobule[5]. In any case, in the fasted state there was essentially no RNAPII

occupancy of *Fasn* gene in either PC or PP hepatocytes with the proximal promoter

pausing peak readily observable in both zones. As expected in the fasted state, RNAPII

occupancy of the *Pck1* gene was high in both the PC and PP hepatocytes (Fig. S2D),

consistent with *Pck1* mRNA expression that is also expressed in both PC and PP

hepatocytes following long-term fasting[5]. However, in contrast to *Fasn* gene, in the fed

"off-state" *Pck1* gene still displayed substantial RNAPII occupancy in the PP

hepatocytes but nearly background levels in the PC hepatocytes (Fig. S2D). As

controls, RNAPII occupancy of *Alb* was neither zonated nor responsive to

fasting/feeding (Fig. S2E) and the RNAPII tracks for *Ins1* was essentially background

(Fig. S2F). These data indicate that the basal (fed state) transcription and expression of

gluconeogenic genes occur predominantly in PP hepatocytes.

Lipogenic and gluconeogenic genes are co-expressed in a subset of periportal

hepatocytes

We next addressed whether all PP hepatocytes or a subset of PP hepatocytes were

responsible for the basal expression of gluconeogenic genes in the fed state. To

address this, we first utilized quantitative targeted single cell RNA-seq (targeted scRNA-

seq) using the 10x genomic platform for a selective subset of metabolic genes[5]. Cell

ranger and Loupe Browser were used for analyses for the quantitative targeted scRNA-

seq to establish UMAP cluster maps of the hepatocytes in the fully fed and fasted states

(Fig. 2A). To identify the position of the PC and PP hepatocytes (Fig. 2B) we took

advantage of previous studies that have characterized the localization of specific

zonation markers[3,5,16]. As examples, the PC markers *Cyp2e1* and *Gulo* (Fig. 2C) were

highly colocalized to one region whereas the PP markers *Cyp2f2* and *Hsd17b13* (Fig.

2D) were highly colocalized to another distinct region. As these genes are typically

expressed as a gradient across the lobule, (with the notable exception of *Glul* that is

highly restricted to hepatocytes in one to two layers around the central vein), the other

lower expressing cells likely represent the mid-zone hepatocytes[1,5]. As expected, in the

fully fed state, the *de novo* lipogenic gene *Fasn* was found in both the PC and PP

hepatocytes but following fasting was essentially absent from all the hepatocytes (Fig.

2E). On the other hand, the gluconeogenic gene *Pck1* was expressed in both the PC

and PP hepatocyte clusters in the fasted state, but also showed expression in a subset

of PP, but not PC, hepatocytes in the fed state (Fig. 2F). Alignment of the UMAPs for

the hepatocytes that co-express both *Fasn* and *Pck1* mRNA in the fed state indicated

they account for 7% of the periportal hepatocytes (Fig. 2G). In addition, comparison of

other core *de novo* lipogenic genes (*Acly*, *Acaca*, and *Elvol6*) with the gluconeogenic

gene *G6pc* also demonstrated that approximately 19% of PP hepatocytes

simultaneously co-expressed these mRNAs (Fig. S3A-E).

Fasn and Pck1 are actively co-transcribed in a subset of periportal hepatocytes

To confirm the scRNA-seq identification of a periportal hepatocyte subset that

simultaneously expresses both gluconeogenic and *de novo* lipogenic genes, we utilized

Hybridization Chain Reaction RNA Fluorescence *in Situ* Hybridization (HCR RNA-FISH)

to simultaneously visualize the transcription sites (TS) of the *Fasn* and *Pck1* genes.

Simultaneous glutamine synthetase RNA-FISH was used to identify the PC region

(Figure 3, *Glul* not shown)[1,5]. In the fed state *Fasn* TS were readily observed throughout

the lobule but fewer *Pck1* TS were detected in a subset of the PP but not PC

hepatocytes (Fig. 3A, Fig. S4A and S4B). Magnified images clearly demonstrated the

presence of both *Fasn* and *Pck1* TS simultaneously in the same nucleus in a subset of

the PP hepatocytes (Fig. 3B). Quantification indicated that 24 % of the periportal

hepatocytes and 1 % of the pericentral hepatocytes displayed TS for both *Fasn* and

Pck1 in the fed state (Fig. 3C). On the other hand, in the fasted state, *Pck1* TS was

readily detected throughout the lobule but with essentially no *Fasn* TS (Fig. 3D, Fig.

S4C and S4D). Magnified images of TS in the fasted state are shown in Fig. 3E.

Quantification indicated that hepatocytes that were dual-positive of TS were not

detected (Fig. 3F). These data directly demonstrate that the subset of PP hepatocytes

actively transcribed both lipogenic (*Fasn*) and gluconeogenic (*Pck1*) genes at the same

time.

Periportal hepatocytes have basal pyruvate-to-glucose flux in the fed state

Gene transcription and mRNA expression does not necessarily indicate functional

activity; we therefore directly determined the relative *de novo* lipogenesis and

gluconeogenesis activities by quantifying the fractional incorporation of ^2H_2O into

palmitate and [2,3-$^{13}C_2$] pyruvate into glucose (Fig. 4). As expected, the fractional

amount of ^2H-palmitate in total hepatocytes from the fed state was substantially higher

(16-fold) compared to hepatocytes from the fasted state (Fig. 4A). The decomposition of

this overall palmitate enrichment is shown as the increased fed vs. fasted isotopologue

enrichment distribution (Fig. 4B). This large increase appears to result from the very low

fractional synthesis in the fasted state. Conversely, the average ^{13}C incorporated per

molecule of glucose synthesized was higher (2.4-fold) in the hepatocytes from the

fasted state compared to the fed state (Fig. 4C). The decomposition of the isotopologue

distribution of glucose is shown in Figure 4D with the majority of glucose isotopologues

synthesized as either M2- or M4-glucose. To address the potential zonation of both

glucose and palmitate synthesis, we next examined the relative synthesis rates in

isolated PC and PP hepatocytes.

Consistent with *Fasn* gene expression, *de novo* lipogenesis activity is relatively high

in the fully fed state (Fig. 4E) with very low activity in the fasted state and exhibits

similar levels between PC and PP hepatocytes. The fold stimulation from the fasted "off"

state and the active fully fed "on" state is approximately 30-fold in PC and 55-fold in PP

hepatocytes. The isotopologue distribution of palmitate is shown in Figure 4F. In

contrast, in the fed state there is a low level of gluconeogenesis from isolated PC

hepatocytes, but it is several-fold higher in the PP hepatocytes (Fig. 4G). In the fasted

state, both PC and PP hepatocytes display a higher rate of gluconeogenesis.

Importantly, the PC hepatocytes increase their gluconeogenic activity ~10-fold, whereas

the PP hepatocytes only increase their gluconeogenic activity ~4-fold due to the higher

basal activity (Fig. 4G). The isotopologue distribution of glucose is shown in Figure 4H,

which again shows mainly the formation of M2- and M4-glucose. These data

demonstrate that in the fed state, PP hepatocytes display a significant degree of

gluconeogenic activity, consistent with the PP expression of gluconeogenic genes in the

fed state. On the other hand, PC hepatocytes exhibit a metabolic plasticity which

enables them to become equally gluconeogenic in the fed to fasted transition.

Dual-positive hepatocytes are insulin resistant in suppression of *Pck1*

Since the fed state is a normal physiologically anabolic state primarily driven by

insulin, the expression of *Pck1* in the fed state suggests that this subset of PP

hepatocytes was less responsive to insulin (i.e., insulin resistant), at least to insulin

suppression of *Pck1* gene expression and gluconeogenic activity. To address this, we

established a quantitative assay to isolate these dual expression (*Fasn* and *Pck1*)

hepatocytes using PrimeFlow that is a combination of *in situ* hybridization coupled with

flow cytometry[17]. As shown in Figure S5A hepatocytes are relatively large cells with a

broad forward (FSC-A) and side scatter (SSC-A) parameters. Primary hepatocytes also

display background fluorescence in the APC-Cy7 and mCherry channels, which were

used for the *Pck1* and *Fasn* fluorescent mRNA probes (Fig. S5B). Nevertheless, in the

fed state there is a substantial increase in the *Fasn* signal, resulting in 75 % of

hepatocytes positive for *Fasn* (Fig. S5C). Similarly, in the fasted state there is a

substantial increase in the *Pck1* signal with 71 % of the hepatocytes positive for *Pck1*

(Fig. S5D). Having established this gating range, when we co-label the fed state

hepatocytes with both the *Pck1* and *Fasn* probes and identified that approximately 12%

of the hepatocytes were dual-positive (Fig. S5E). With a quantitative method in hand,

we determined the number of dual *Pck1*/*Fasn* positive hepatocytes relative to the single

positive and dual negative hepatocytes and performed euglycemic-hyperinsulinemic

clamps in the 24-hour fasted state and the fed state at various insulin infusion rates. We

also determined the relative suppression of the *Pck1* and *G6pc* mRNA in total

hepatocytes. Under these conditions, the fasted *Pck1* and *G6pc* mRNA expression

levels significantly decreased at 0.3 mU/kg/min (Fig. S5F and S5G). In contrast, fed

Pck1 mRNA in the dual-positive hepatocytes was not suppressed until 2 mU/kg/min of

infused insulin (Fig. S5H). These data directly demonstrate that the *Fasn*/*Pck1* dual-

positive hepatocytes are transcriptionally insulin resistant compared to the bulk liver

hepatocytes.

Together these findings demonstrate that a subset of PP hepatocytes simultaneously

express both gluconeogenic and lipogenic genes in the fed state (Figs. 2, 3, S3 and

S4), and that isolated PP hepatocytes can also display both gluconeogenic and *de novo*

lipogenic activities in the fed state (Fig. 4). However, this data does not directly

demonstrate that individual dual-positive hepatocytes are in fact dual functional. To test

for this possibility, we employed single cell spatial metabolic imaging to simultaneously

assess both gluconeogenic and *de novo* lipogenic activities within individual

hepatocytes

A subset of liver regions has higher ATP turnover in the fed state

Depending upon the substrate, gluconeogenesis requires 6-10 ATP molecules per

molecule of glucose generated. Similarly, synthesis of palmitate from acetyl-CoA

requires 7 ATP and 14 NAPDH molecules. Thus, if a single hepatocyte is

simultaneously engaged in both gluconeogenesis and *de novo* lipogenesis, it can be

hypothesized that there must necessarily be a high rate of ATP turnover compared to

the other bulk hepatocytes. During the process of energetic addition of phosphates to

nucleotides or metabolites, there is an exchange of the oxygen in the phosphate with

the oxygen in cell water[18-21]. ATP turnover reflects the percentage of ^{16}O in ATP

replaced by ^{18}O after the *in vivo* administration of ^{18}O-labeled water, reflecting whole

cell energetics, as the exchange of ^{18}O in high energy phosphates includes ATP

synthesis and ATP hydrolysis, and the ^{18}O can also be exchanged with creatine kinase

and adenylate kinase catalyzed phosphotransfer[22,23] (Table S1). Thus, we treated mice

with or without ^{18}O labeled water *in vivo* coupled with spatial imaging by DESI-Cyclic

IMS TOF. Figure 5 shows liver sections from the fed and 24 h fasted state that were

either untreated (unlabeled) or treated with ^{18}O labeled water as we previously reported

[23]. Mass spectrometry imaging was done at 60x60 µm for the mass of normally

abundant m0 (unlabeled) AMP in the negative ion mode. As mouse hepatocytes are

polygonal and are nominally 20-30 µm in diameter, this resolution likely reflects the

combination of several cells[24]. Regardless, the relative amount of the m0 AMP indicated

a relatively low signal in the fed state but was markedly increased in the fasted state,

indicating a greater turnover of AMP in the fasted state (Fig. 5A). In contrast, imaging

for ^{18}O-labeled AMP (m0+2 AMP) demonstrated an increased signal from background

in both the fasted and fed states, from the mice treated with ^{18}O labeled water

compared to control mice livers (Fig. 5B). More importantly, the liver cross-section in the

fasted state showed increased intensities suggesting increased turnover relative to the

fed state (Fig. 5B). In contrast, m0+2 ADP fasted and fed intensities were similar over

each slice, suggesting turnover was similar between the fed and fasted state. The

increase of m0+2 ATP intensities over the liver cross-section suggested turnover was

increased in the fed state compared to the fasted state, which would correspond to an

increase in ATP generation in the fed state (Fig. 5C). As these AMP, ADP and ATP

measurements were done on the same slice, m0+2 ADP and m0+2 ATP pixel densities

can be compared to m0+2 AMP in fed state with multiple sites of overlap between m0+2

AMP, ADP and ATP (Fig. 5D). These results revealed several discrete pixels that

clearly overlapped between m0+2 AMP (red), ADP (blue) and ATP (green) (Fig. 5D).

The white areas indicate pixel regions with strong overlap for all three signals. These

data strongly indicate that a small subset of liver regions have higher rates of ATP, ADP

and AMP turnover in the fed state, indicating increased energetics, which might be

expected for Dual-Modal hepatocytes.

A subset of hepatocytes is lipogenic and gluconeogenic

To more specifically address whether an individual hepatocyte can simultaneously

undergo both *de novo* lipogenesis and gluconeogenesis, we next utilized metabolic

spatial imaging to identify the formation of m0+4 palmitate (*de novo* lipogenesis) and

m0+3 glucose-6-phosphate (gluconeogenesis) from a liver section of mice *in vivo* fed

with U[^{13}C]-glucose. m0+3 glucose-6-phosphate (3 labeled carbons) can only be formed

from U[^{13}C]-glucose (6 labeled carbons) when the m0+6 glucose is metabolized to a

m0+3 triose. The triose then goes up the gluconeogenic pathway to glucose or first

down the glycolytic pathway into the TCA cycle and then back up the glycolytic pathway

to form glucose (Fig. 6A). On the other hand, labeled palmitate can only be formed if the

U[^{13}C]-glucose becomes m0+3 pyruvate and then enters the TCA cycle through

pyruvate dehydrogenase to generate the 2-carbon labeled acetyl-CoA. Subsequent

metabolism and addition of these 2-carbon labeled units for fatty acid synthesis results

in the formation of m0+2, m0+4 etc. labeled palmitate (Fig. 6A). The dual-imaging of

m0+4 palmitic acid (red) and m0+3 glucose-3-phosphate (blue) by DESI MSI at 25 x 25

µm demonstrated the presence of pixels that were dual positive for both (pink, indicated

by arrows) (Fig. 6B). The same experiment was performed with MALDI MSI in a lower

magnification (50 x 50 µm). The ingestion of U[^{13}C]-glucose in the fed state resulted in

the appearance of m0+4 palmitate acid (red) and m0+3 glucose-6-phosphate (blue)

throughout the liver section whereas there was no detectable background labeling when

ingestion of unlabeled glucose in a parallel mouse (Fig. 6C). A higher magnification of

this MALDI image showed the presence of pixels that were dual positive for both m0+4

palmitic acid and m0+3 glucose-6-phosphate (pink, indicated by arrows) (Fig. 6D).

Since this resolution does not provide single cell information[24], we next performed mass

spectrometry spatial imaging at 10 μm resolution for m0+4 palmitic acid (red) and m0+3

glucose-6-phosphate (blue) that we co-registered with H&E staining (Fig. 6E and F). As

is apparent, in this imaging each pixel is smaller than the hepatocytes and with a high

probability it represents a single hepatocyte (Fig. 6E and F). Consistent with the lower

resolution image, individual hepatocytes mostly display *de novo* lipogenesis in the fed

state (m0+2 palmitic acid positive, red) with fewer hepatocytes positive for m0+3

glucose-6-phopshate (blue). However again, there were several pixels in the field that

are dual positive (pink), consistent with the overlap seen with ATP, ADP and AMP

turnover (Fig. 5) and the dual-positive hepatocytes present as measured by both

scRNA-seq and PrimeFlow. As these data confirm the metabolic functional duality

(simultaneous gluconeogenic and *de novo* lipogenic activities), we have termed these

as Dual-Modal hepatocytes.

Humanized mouse liver has dual-positive spots

Having established the presence of hepatocyte subsets that simultaneously express

both *Fasn* and *Pck1* mRNA in the fed state of mouse liver, we addressed whether dual-

positive hepatocytes are also present in human liver hepatocytes. As patient surgical

interventions can only be performed in the fasted state, it is not possible to obtain liver

specimens or biopsy samples from humans in the fed state. Thus, we utilized a

humanized mouse model in which human hepatocytes replace greater than 95 % of the

mouse hepatocytes and performed 10x Genomics spatial transcriptomics Visium

analyses on liver sections[25].Similar to the mice data, RT-qPCR for human *Fasn* showed

relatively low expression in the fasted state with induction in the fed state (Fig. S6A).

Additionally, the human *Fasn* PCR primers were unable to detect *Fasn* mRNA in wild-

type mouse liver, indicating no cross-reactivity. Similarly, the human *pck1* PCR primers

did not cross-react with mouse *Pck1* but clearly displayed the fasted state induction of

Pck1 (Fig. S6B). As the Visium protocol requires a prior fixation step, we also confirmed

that this fixation step did not disrupt the integrity of mRNA detection by RT-qPCR (Fig.

S6C and D). Relative differences in the expression of the human PC marker (*CYP1A2*)

and PP marker (*HSD17B13*) as shown in the violin plots (Fig. S6E and S6F) enabled

the identification of PC spots (blue) and PP spots (red) (Fig. S6G). The violin plots for

Fasn (Fig. S6H) and *Pck1* (Fig. S6I) display the expected zonation, in particular the

Pck1 mRNA in the PP hepatocytes are elevated compared to those of the PC

hepatocytes. The distribution of the *Fasn*/*Pck1* dual-positive spots is marked in yellow

with the H&E staining of the section (Fig. S6J) and with a magnified region show in

Figure S6K. Quantification showed 9% of the PP hepatocytes were *Fasn*/*Pck1* dual-

positive (Fig. S6L). These results suggest Dual-Modal hepatocytes presumable exist in

human hepatocytes as well.

Dual-positive spots increase in high-fat diet fed mice liver

Lastly, having established the Dual-Modal (*Fasn*/*Pck1* positive) hepatocytes that are

naturally insulin resistant (Fig. S4) and are gluconeogenic in the fed state, we

speculated that in states of insulin resistance the number of these hepatocytes might

increase. To test this hypothesis, we determined the number of Dual-Modal hepatocytes

in mice fed a normal chow diet (NCD) or a high-fat diet for 3 months (3MHFD) and used

the Visium platform for spatial single dot analyses. t-SNE plots showed separation

between NCD and 3MHFD (Fig. S7A). Graph-based clustering showed zonation

patterns in both NCD and 3MHFD (Fig. S7B, S7C). Based on analyses of several

zonation markers such as *Cyp2e1* and *Glul* for pericentral (Fig. S7D) and *Cyp2f2* and

Hsd17b13 for periportal (Fig. S7E), we identified the PC (pink) and PP (blue) spots in

the t-SNE plot, showing clear separation (Fig. S7F). The PC and PP regions in

comparison with histological H&E staining are shown in Figure 7A. The presence of lipid

droplets in the HFD fed mice that are specifically localized to the PC hepatocytes is

readily observed in the magnified region shown in Figure 7B, consistent with the known

zonation of triglyceride accumulation[26]. The distribution of zonation markers as violin

plots is shown in Figures 7C and 7D. As expected for the fed state, *Fasn* mRNA was

expressed in both PC and PP hepatocytes in both the NCD and 3MHFD fed mice (Fig.

S7G). Consistent with our previous findings, *Pck1* mRNA was also present in a subset

of periportal hepatocytes (Fig. S7H) that overlapped with the *Fasn* dots (Fig. S7G). The

overlap of *Fasn* and *Pck1* mRNA positive dots in the NCD and HFD fed mice is shown

in Figures 7E. Quantification of the number of dots that were dual positive was

approximately 4 % under NCD diet but following 3 months of HFD the number of dual

positive dots increased to approximately 13 % (Fig. 7F). Moreover, these overlapping

dots primarily occurred in the PP region (Fig. 7G). These data demonstrate that long

term HFD results in an increase in the number of the Dual-Modal (*Fasn*/*Pck1* positive)

hepatocytes.

DISCUSSION

Gluconeogenesis is a fundamental metabolic process in which non-carbohydrate

carbon substrates such as lactate, glycerol and amino acids are used to generate

glucose[2,27]. In mammals' gluconeogenesis is primarily performed in the hepatocyte,

although kidney and intestine cells are capable of driving significant gluconeogenesis as

well[27-29]. In general, gluconeogenesis is inhibited in the fed state when plasma glucose

levels rise as a result of dietary absorption, and insulin secretion is stimulated. In the

fasted state, dietary derived plasma glucose levels decline, reducing insulin secretion

and stimulating glucagon and epinephrine release to activate hepatic gluconeogenesis

and glucose release to restore and maintain a normal glycemic state. Two of the key

gluconeogenic enzymes phosphoenolpyruvate carboxykinase (gene *Pck1*) and glucose

6-phosphate catalytic subunit (gene *G6pc*) are not thought to be allosterically regulated,

but acutely controlled at the level of gene expression through upstream transcription

factors that are activated by protein kinase A (i.e., CREB, HNF4α, FoxO1) signaling and

suppressed by insulin signaling[27].

Despite this generalized regulation of hepatic gluconeogenic gene expression and

gluconeogenic activity in the fed and fasted states, previous studies assessing

gluconeogenesis observed a basal level of glucose production from the liver even in the

fed state[6,7]. In fact, examination of numerous hyperinsulinemic-euglycemic clamp data

clearly shows that an insulin suppression of hepatic glucose production is never

zero[30,31]. This has been typically ignored and assumed to simply represent a

background signal. Our data suggest otherwise, as the mRNA expression and

transcription of lipogenic genes are essentially zero in their respective off-state (fasted),

whereas there is always a measurable level of gluconeogenic gene expression,

transcriptional activation and gluconeogenic activity in their respective off-state (fed).

This fed state mRNA expression of *Pck1* was confirmed by multiple, independent

methodologies, including targeted quantitative single cell RNAseq, smFISH, HCR RNA-

FISH and PrimeFlow. Moreover, PrimeFlow demonstrated the presence of both mRNA

for *Fasn* and *Pck1* in the same cells and HCR RNA-FISH clearly visualized the same

nuclei displaying transcription sites for both *Fasn* and *Pck1*. Each of these assays

indicated a subset of periportal hepatocytes is dual *Fasn* and *Pck1* positive in the fed

state.

Hepatocyte zonation is well established as a property of regionally distinct cellular

functions localized across the liver lobule, and studies in the 1980's using fasted rats

reported that there was a 2 to 3-fold bias of gluconeogenesis in isolated PP hepatocytes

relative to PC hepatocytes[14,32]. We also found an approximate 1.4-fold bias in

gluconeogenic activity and *Pck1* gene expression in PP versus PC hepatocytes of

fasted mice. However, analyses of gluconeogenic activity in the fed state, although

absolutely less than in the fasted state, was approximately 3.2-fold greater in PP versus

PC hepatocytes. In parallel, very few *Pck1* transcription sites and very low levels of

Pck1 mRNA or protein were detected in fed PC hepatocytes compared to PP

hepatocytes. These data are consistent with a subset of PP hepatocytes being

responsible for the basal (fed state) level of gluconeogenesis. As such, we refer to this

hepatocyte subset as Dual-Modal (DM) hepatocytes.

The conversion of U[^{13}C]-glucose to m0+2- and m0+4-palmitate is generally

accepted as a direct measure of *de novo* lipogenesis that is readily detected by mass

spectrometry imaging[33]. However, spatial mass spectrometry imaging cannot detect

labeled glucose within a hepatocyte, as glucose is rapidly secreted. Instead, we

measured hepatocyte content of m0+3-glucose-6-phosphate derived from ingested

U[^{13}C]-glucose. In order for U[^{13}C]-glucose to generate m0+3-glucose-6-phosphate, the

U[^{13}C]-glucose must at minimum be converted by glycolysis or the pentose cycle into

the triose pool, which in turn can either enter the TCA cycle (pyruvate->oxaloacetate-

>PEP->triose-P pool) for gluconeogenesis/glyceroneogenesis, or the trioses glycerol-3-

phosphate and dihydroacetone phosphate recombine to form fructose-1,6-phosphate

and subsequently glucose-6-phosphate. Regardless of whether recycled glucose is

derived from the triose-P pool after traveling to the triose-P pool via glycolysis and the

TCA cycle or the pentose cycle and/or via the TCA cycle, our finding of the generation

of m0+3-glucose-6-phosphate from ingested U[^{13}C]-glucose demonstrates that in the

fed state, a subset of hepatocytes exhibits a simultaneous, bidirectional metabolic flow

up and down the glycolytic pathway. Our finding that isolated PP hepatocytes in the fed

state generate secreted glucose is consistent with a novel demonstration of

gluconeogenesis in the fed state.

However, these data do not rule out other metabolic pathways for the generation of

stable isotope labeled trioses. For example, the trioses could also contribute to

glyceroneogenesis that in the fed state are needed for the generation of the backbone

for triacylglycerol synthesis. Another more intriguing possibility is that the formation of

m0+3 glucose-6-phosphate in the fed state may account for previous observations

supporting an indirect pathway for glycogen synthesis[8-11]. After glycogen is depleted in

the fasted state, it can be re-synthesized in the fed state by the direct pathway (dietary

glucose converted to glucose-6-phosphate epimerized to glucose-1-phosphate that

generates UDP-glucose for direct addition to glycogen[9,11]. Alternatively, glucose but

also gluconeogenic substrates (i.e., amino acids) can be used to generate trioses by

cycling down the glycolytic pathway into the TCA cycling and then metabolized via

pyruvate carboxylase then PEPCK to generate triose-P which can then generate

glucose-6-phosphate that is then used for the re-synthesis of glycogen[8-11]. Additional

stable isotope flux analyses will be necessary to distinguish between these distinct

routes of carbohydrate flux in this unique hepatocyte subpopulation, and which likely are

not mutual exclusive.

While we observed that both normal mouse liver as well as humanized mouse livers

express naturally insulin resistant, Dual-Modal hepatocytes, their functions in systemic

physiology and pathophysiology remain to be determined. One possibility is that during

ingestion of ketogenic diets, glucose, although lowered, still needs to be produced. In

this case, Dual-Modal hepatocytes could provide a mechanism to maintain basal

glycemic levels necessary for survival. Pathophysiologically, high-fat diet induced insulin

resistance resulted in an increase in the number of Dual-Modal hepatocytes. This opens

up the intriguing possibility that the change in proportion of this unique hepatocyte

subpopulation may be an important component leading to hepatic insulin resistance.

Limitations of the study

While we have identified a subset of hepatocytes termed Dual-Modal hepatocytes

that could potentially explain the cause of hepatic insulin resistance based on an

increased number of Dual-Modal hepatocytes in high-fat diet fed mice, it is important to

recognize that these data do not distinguish between whether the number of Dual-

Modal hepatocytes increase due to proliferation of the pre-existing Dual-Modal

hepatocyte subpopulation and/or due to the development of insulin resistance in normal

hepatocytes. Future lineage tracing studies will be necessary to assess these two

possibilities. Also, this study does not molecularly address how an individual cell can

apparently undergo gluconeogenesis and *de novo* lipogenesis at the same time, as

these two metabolic pathways are generally assumed to be mutually exclusive with

each other. The three most likely possibilities are i) futile cycling throughout the parallel

glycolytic and gluconeogenic pathways for either periportal and/or pericentral

hepatocytes (dependent on degree of fasted or refed states) thereby allowing

substrates to flow in both directions; ii) relatively rapid oscillations between

gluconeogenesis and *de novo* lipogenesis, perhaps operant in Dual-Modal hepatocytes,

so that they are not actually occurring simultaneously; and iii) subcellular

compartmentalization of metabolic flux such that different regions or mitochondria within

an individual hepatocyte can undergo either gluconeogenesis or *de novo* lipogenesis.

RESOURCE AVAILABLITY

Lead contact

Further information and requests for resources and reagents should be directed to and

will be fulfilled by the lead contact, Junichi Okada (junichi.okada@einsteinmed.edu)

Materials availability

This study did not generate new unique reagents.

Data and code availability

Raw ChIP and fastq files were deposited in the National Center for Biotechnology Information Gene Expression Omnibus database and are available under accession numbers: GSE315776, GSE263419 (previously published targeted scRNA-seq data) and GSE320372 (VISIUM). This study was conducted using only publicly available software; no custom code was used.

ACKNOWLEDGEMENTS

We wish to acknowledge that the data presented in this manuscript was made possible through the expertise of The Albert Einstein College of Medicine Genomics, Animal Physiology, Flow Cytometry and Metabolomics Core Facilities. We are thankful to Floric Slimani for the smallFish package, Licheng Wu for euglycemic-hyperinsulinemic clamp studies, and Shiori Okada for data analysis. This study was supported by NIH grants DK020541, DK110063, DK069861, GM007491, CA013330, AI179019, AA031412, and the PhoenixBio R&D Grant.

AUTHOR CONTRIBUTIONS

JO, AL, MH, AMX, RR, SVL, TS, GJS, CE, RCS, YQ and IJK all assisted in the experimental design, performance and analyses of the data presented, and writing of the manuscript. LL and KS assisted in the experimental design, bioinformatic analyses and editing of the manuscript. VLS, FY, MH, CE, KS and JEP supervised this project, experimental design, interpretation of data and writing the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

FIGURE LEGENDS

Figure 1 *Pck1* is transcribed in hepatocytes in the fed state. (A) Relative mRNA

levels of *Fasn* in fed/fasted total hepatocytes. (B) Relative mRNA levels of *Pck1* in

fed/fasted total hepatocytes. (C) Relative mRNA levels of *Alb* in fed/fasted total

hepatocytes. (D) RNAP II ChIP of *Fasn* in fed/fasted total hepatocytes. (E) RNAP II

ChIP of *Pck1* in fed/fasted total hepatocytes. (F) RNAP II ChIP of *Alb* in fed/fasted total

hepatocytes. (G) RNAP II ChIP of *Ins1* in fed/fasted total hepatocytes.

Figure 2 *Fasn* and *Pck1* are co-expressed in a subset of periportal hepatocytes.

(A) UMAP visualizations of the targeted scRNA-seq based on feeding conditions. (B)

UMAP visualizations based on zonation. (C) UMAP of PC zonation markers *Cyp2e1*

and *Gulo.* (D) UMAP of PP zonation markers *Cyp2f2* and *Hsd17b13.* (E) UMAP of *Fasn*

positive hepatocytes. (F) UMAP of *Pck1* positive hepatocytes (G) UMAP of dual-positive

hepatocytes.

Figure 3 *Fasn* and *Pck1* are actively co-transcribed in a subset of periportal

hepatocytes. (A) HCR RNA-FISH image of *Pck1* (magenta) and *Fasn* (green) with

DAPI-stained nuclei (blue) in the fed state (representative image shown). Lobules show

the central vein (CV) on the left and the portal vein (PV) on the right. (B) Magnified

images of nuclei in box in panel (A). Arrows show transcription sites (TSs) (green

arrow=*Fasn*, white arrow=*Pck1*, individual channel images of *Pck1* and *Fasn* are shown

in Figure S4A and S4B). (C) Quantitative analysis of TSs in the fed state. Lines connect

TS quantification between PC and PP within a lobule (N=21 lobules). Data are from 3

individual mice and are represented with different colors. Mean ± s.d. is indicated. *P*-

value was calculated by paired *t*-test, N.S. if not indicated. 627 PC nuclei, 632 PP nuclei

were analyzed, Scale bar, 20 um. (D) HCR-RNA FISH image of *Pck1* (magenta) and

Fasn (green) with DAPI-stained nuclei (blue) in the fasted state (representative image

shown). Lobules show the central vein (CV) on the left and the portal vein (PV) on the

right. (E) Magnified images of nuclei in box in panel (D). White arrows highlight Pck1 TS

(individual channel images of *Pck1* and *Fasn* are shown in Figure S4C and S4D). (F)

Quantitative analysis of TS in the fasted state. Lines connect TS quantification between

PC and PP within a lobule (N=21 lobules). Data are from 3 individual mice and are

represented with different colors. Mean ± s.d. is indicated. *P*-value was calculated by

paired *t*-test, N.S. if not indicated. 705 PC nuclei, 822 PP nuclei were analyzed, Scale

bar, 20 um.

Figure 4 Periportal hepatocytes have basal pyruvate-to-glucose flux in the fed

state. (A) *De novo* palmitate measurements using deuterated water in total hepatocytes

from fed (n=4) and fasted (n=4) mice. Data are presented as mean values; error bars,

s.d. Comparison between groups was made with unpaired, two-tailed Student's *t*-test

(***P < 0.001). (B) Fed and fast palmitate isotopologues derived from ^2H_2O in total

hepatocytes. (C) ΣM_n (average ^{13}C carbons per molecule) of glucose derived from [2,3-

$^{13}C_2$]-pyruvate in total hepatocytes from fed (n=3) and fasted (n=5) mice. Data are

presented as mean values; error bars, s.d. Comparison between groups was made with

unpaired, two-tailed Student's *t*-test (***P < 0.001). (D) Fed and fast glucose

isotopologues derived from [2,3-^{13}C$_2$]-pyruvate in total hepatocytes. (E) De novo

palmitate measurements using deuterated water in PC/PP hepatocytes from fed (n=4)

and fasted (n=4) mice. Data are presented as mean values; error bars, s.d. Comparison

between groups was made with unpaired, two-tailed Student's *t*-test (**P < 0.01). (F)

Fed and fast palmitate isotopologues derived from ^{2}H$_2$O in PC/PP hepatocytes. (G) ΣM_n

(average ^{13}C carbons per molecule) of glucose derived from [2,3-^{13}C$_2$]-pyruvate in

pericentral (PC) and periportal (PP) hepatocytes from fed and fasted mice (n=5 for PC,

n=6 for FastPP, n=7 for FedPP). Data are presented as mean values; error bars, s.d.

Comparison between groups was made with unpaired, two-tailed Student's *t*-test (***P <

0.001). (H) Fed and fast glucose isotopologues derived from [2,3-^{13}C$_2$]-pyruvate in

PC/PP hepatocytes.

Figure 5 A subset of liver regions has higher ATP turnover in the fed state. (A)

Representative DESI image of unlabeled AMP (M0) from unlabeled and 18O labeled

water intraperitoneal+gavage mice in the fed and fasted state. (B) Representative DESI

image of labeled AMP (m0+2) from unlabeled and 18O labeled water

intraperitoneal+gavage mice in the fed and fasted state. (C) Representative DESI image

of labeled ADP (m0+2) (left) and ATP-Na (m0+2) (right) from 18O labeled water

intraperitoneal+gavage mice in the fed and fasted state. (D) Representative DESI image

of labeled AMP (m0+2, red), ADP (m0+2, blue), and ATP-Na (m0+2, green) merged as

one image. The white areas indicate pixel regions with strong overlap for all three

signals.

Figure 6 A subset of hepatocytes is lipogenic and gluconeogenic. (A) Scheme of

detecting Dual-modal (DM) spots with U^{13}C glucose. (B) 25 x 25 μm DESI image of

U[^{13}C]-glucose labeled m0+4 Palmitic acid (red) and m0+3 Glucose-6-phosphate (blue);

pink represent the DM spots. White arrows highlight the DM spots. (C) Low

magnification MALDI image of U[^{13}C]-glucose labeled m0+4 Palmitic acid (red) and

m0+3 Glucose-6-phosphate (blue); pink represent the DM spots, unlabeled glucose

section as control. Each pixel is 50 μm. (D) High magnification MALDI image of U[^{13}C]-

glucose labeled m0+4 Palmitic acid (red) and m0+3 Glucose-6-phosphate (blue); pink

represent the DM spots. White arrows highlight the DM spots. Each pixel is 50 μm. (E)

High magnification of H&E staining. (F) High magnification MALDI image of U[^{13}C]-

glucose labeled m0+2 Palmitic acid (red) and m0+3 Glucose-6-phosphate (blue); pink

represent the DM hepatocytes. White arrows highlight the DM hepatocytes. Each pixel

is 10 μm.

Figure 7 Dual-positive spots increase in high-fat diet fed mice liver. (A) Spatial

transcriptomics image of Normal Chow Diet (NCD) fed mice and 3 Month High Fat Diet

(3MHFD) fed mice with Pericentral (PC)/Periportal (PP) spots highlighted. (B) A

representative lobule shown in a higher magnification with central vein (CV) on the left,

portal vein (PV) on the right. Pink spots are PP, blue spots are PC. (C) Violin plot of

Cyp2e1 (pericentral (PC) marker) log normalized expression in PC/PP spots of NCD

and 3MHFD fed mice. (D) Violin plot of *Cyp2f2* (periportal (PP) marker) log normalized

expression in PC/PP spots of NCD and 3MHFD fed mice. (E) Distribution of DM spots in

NCD and 3MHFD fed mice; yellow spots show DM spots. (F) Quantification of DM spots

in NCD and 3MHFD fed mice. (G) Quantification of DM spots in PC/PP spots of NCD

and 3MHFD fed mice.

Supplementary Figures

Figure S1 *G6pc* is transcribed in hepatocytes in the fed state. (A) RNAP II ChIP of

Acly in fed/fasted total hepatocytes. (B) RNAP II ChIP of *Elovl6* in fed/fasted total

hepatocytes. (C) RNAP II ChIP of *G6pc* in fed/fasted total hepatocytes.

Figure S2 *Pck1* is transcribed in periportal hepatocytes in the fed state. (A)

Relative mRNA levels of *Cyp2e1* in in fed/fasted PC/PP hepatocytes. (B) Relative

mRNA levels of *Cyp2f2* in in fed/fasted PC/PP hepatocytes. RNAP II ChIP of *Fasn* in

fed/fasted PC/PP hepatocytes. (D) RNAP II ChIP of *Pck1* in fed/fasted PC/PP

hepatocytes. (E) RNAP II ChIP of *Alb* in fed/fasted PC/PP hepatocytes. (F) RNAP II

ChIP of *Ins1* in fed/fasted PC/PP hepatocytes.

Figure S3 *Acly*, *Acaca*, *Elovl6*, and *G6pc* are co-expressed in a subset of

hepatocytes. (A) UMAP of *Acly* positive hepatocytes. (B) UMAP of *Acaca* positive

hepatocytes. (C) UMAP of *Elovl6* positive hepatocytes. (D) UMAP of *G6pc* positive

hepatocytes.

Figure S4 *Pck1* is actively transcribed in the fed state. (A) HCR RNA-FISH image of

Pck1 (magenta) with DAPI-stained nuclei (blue) in the fed state (representative image

shown). Lobules show the central vein (CV) on the left and the portal vein (PV) on the

right. (B) HCR RNA-FISH image *Fasn* (green) with DAPI-stained nuclei (blue) in the fed

state (representative image shown). Lobules show the central vein (CV) on the left and

the portal vein (PV) on the right. (C) HCR RNA-FISH image of *Pck1* (magenta) with

DAPI-stained (blue) in the fasted state (representative image shown). Lobules show the

central vein (CV) on the left and the portal vein (PV) on the right. (B) HCR RNA-FISH

image *Fasn* (green) with DAPI-stained (blue) in the fed state (representative image

shown). Lobules show the central vein (CV) on the left and the portal vein (PV) on the

right. Scale bar, 20 um.

Figure S5 Dual-positive hepatocytes are insulin resistant in suppression of *Pck1*.

(A) Flow cytometry gating strategy utilizing FSC-A and SSC-A for size selection of

hepatocytes. (B) Background fluorescence of hepatocytes. (C) Gating of *Fasn* based on

fed hepatocytes. (D) Gating of *Pck1* based on fasted hepatocytes. (E) Representative

flow cytometry result of *Fasn*/*Pck1* in the fed state; the red quadrant shows the Dual-

modal (DM) hepatocytes. (F) Insulin suppression of *G6pc* mRNA expression based on

hyperinsulinemic-euglycemic clamps on fasted hepatocytes. (G) Insulin suppression of

Pck1 mRNA expression based on hyperinsulinemic-euglycemic clamps on fasted

hepatocytes. (H) Insulin suppression of *Pck1* mRNA expression on DM hepatocytes

based on hyperinsulinemic-euglycemic clamps in the fed state.

Figure S6 Humanized mouse liver has dual-positive spots. (A) Relative mRNA

levels of human *Fasn* from fresh frozen liver tissue (mouse liver vs. humanized liver,

fed/fasted). (B) Relative mRNA levels of human *Pck1* from fresh frozen liver tissue

(mouse liver vs. humanized liver, fed/fasted). (C) Relative mRNA levels of human *Fasn*

from 4% PFA fixed liver sections (humanized liver). (D) Relative mRNA levels of human

Pck1 from 4% PFA fixed liver sections (humanized liver). (E) Violin plot of *Cyp1a2* (PC

marker) log normalized expression. (F) Violin plot of *Hsd17b13* (PP marker) log

normalized expression. (G) Spatial Transcriptomics slide from fed mice with Pericentral

(PC)/Periportal (PP) spots highlighted. (H) Violin plot of *Fasn* (lipogenic gene) log

normalized expression. (I) Violin plot of *Pck1* (gluconeogenic gene) log normalized

expression. (J) Spatial Transcriptomics slide from fed mice with Dual-Modal (DM) spots

highlighted. (K) DM spots image with PC/PP alignment. (L) Percentage of DM spots in

PC/PP regions.

Figure S7 t-SNE separates NCD and 3MHFD. (A) t-SNE visualization of spatial

transcriptomics based on feeding conditions (Normal Chow Diet (NCD) and 3-Month

High-Fat Diet (3MHFD). (B) Spatial transcriptomics image of NCD fed mice and 3MHFD

fed mice with graph-based clustering highlighted. (C) t-SNE visualization of spatial

transcriptomics based on graph-based clustering. (D) t-SNE visualization of pericentral

markers *Cyp2e1* and *Glul*. (E) t-SNE visualization of periportal markers *Cyp2f2* and

Hsd17b13. (F) t-SNE visualization of spatial transcriptomics based on zonation. (G)

spatial transcriptomics image of *Fasn* positive spots in NCD and 3MHFD fed mice. (H)

spatial transcriptomics image of *Pck1* positive spots in NCD and 3MHFD fed mice.

694 **Table S1 Compendium of $^{18}O/^{16}O$ exchange reactions which determine ATP**

695 **turnover.**

696

697 **Table S2 Primer Sequences**

698

699 **METHODS**

700 **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
RNAPII subunit B1 (Rpb1) NTD	Cell Signaling	14958
Chemicals, peptides, and recombinant proteins		
Liberase	Sigma-Aldrich	5401127001
Digitonin	Sigma-Aldrich	D141-500MG
Percoll	Sigma-Aldrich	P4937-500ML
Critical commercial assays		
ChIP DNA Clean & Concentrator kit	Zymo Research	D5205
NEBNext® Ultra™ II DNA Library Prep Kit	New England Biolabs	E7645
HCR RNA-FISH	Molecular Instruments	V3.0 (N/A)
PrimeFlow RNA Assay Kit	Invitrogen	88-18005-204
Deposited data		
ChIP sequence	This paper, GEO	GSE315776
Targeted scRNA-seq	Okada et al[5], GEO	GSE263419
Visium (spatial transcriptomics)	This paper, GEO	GSE320372
Experimental models: Organisms/strains		
C57Bl/6J	The Jackson Lab	000664
Oligonucleotides		
Illumina® single Index Primers Set 1	New England Biolabs	E7335
Illumina® single Index Primers Set 2	New England Biolabs	E7500
See Table S2 for primer sequences	This paper	N/A
Software and algorithms		
Trim Galore	Krueger et al	https://github.com/FelixKrueger/TrimGalore, V0.6.7

Bowtie2	Langmead et al[34]	V2.4.5
Samtools	Li et al[35]	V1.6
DeepTools	Ramirez et al[36]	V3.5.1
Cell Ranger	10x Genomics	V6.0.1
Small Fish (Cellpose-SAM, big-fish)	Slimani et al	https://github.com/SmallFishGUI/small_fish_gui, V2.1.10
Space Ranger	10x Genomics	V2.0.0, V3.1.0
Other		
PicoLab Rodent Diet 20	LabDiet	5053
Rodent Diet with 60 kcal% Fat	Research Diets	D12492
Modified OSD with Macronutrient Content Similar to LabDiet 5053	Research Diets	D17011901px

EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

Animals

All animal studies were conducted in accordance with protocols approved by the Albert

Einstein College of Medicine Institutional Animal Care and Use Committee (IACUC).

Unless otherwise indicated, experiments were performed using 10-14-week-old

C57Bl/6J wild-type male mice (The Jackson Laboratory, 000664). Spatial

transcriptomics studies were performed using 18-week-old mice. Animals were housed

in an IACUC-approved facility under ambient temperature and humidity with a 12-hour

light/dark cycle (lights turn on 7:00, lights turn off 19:00) and group housing. Mice had

free access to water and laboratory mouse chow diet (LabDiet, 5053), unless otherwise

specified. For high-fat diet studies, mice were fed a 60% fat diet (Research Diets,

D12492) beginning at 6 weeks of age for 3 months.

To align feeding conditions, mice were trained for 3 days to a time-restricted feeding

schedule by removing food at 17:00 and refeeding at 9:00 the following day (16-hour

fasting and 8-hour feeding) as previously described[5,12]. On the day of the experiment,

mice were provided food with drinking water supplemented with 20% sucrose (w/v) at

9:00. Fed mice were sacrificed at 13:00, corresponding to 4 hours of feeding. For fasted

mice, food and sucrose-containing water were removed at 13:00, drinking water was

replaced with regular water, and mice were fasted for 24 hours before sacrifice at 13:00

the following day. For pericentral/pericentral ChIP sequencing studies, mice were

sacrificed after 16 hours of fasting. For high-fat diet studies (and control mice), food was

removed at 7:00, refed at 19:00, and sacrificed at 23:00 (12-hour fasting and 4-hour

feeding).

Humanized liver chimeric mice

uPA SCID-based humanized liver chimeric mice were generated as previously

described and maintained with vitamin C containing chow diet (modified LabDiet 5053

containing 130 ppm vitamin C)[25]. Humanized liver chimeric mice were subjected to a

time-restricted feeding schedule modified to 10-hour fasting and 14-hour feeding.

METHOD DETAILS

Hepatocyte Isolation

Liver perfusion and hepatocyte isolation were performed under anesthesia as previously

described[5]. For total hepatocyte isolation, a catheter was placed in the portal vein (PV)

and the lower inferior vena cava (IVC) was cut for drainage. For zonated hepatocyte

isolation, catheters were placed in both the PV and IVC, and the perfusion line was

connected to the PV for periportal (PP) isolation of to the IVC for pericentral (PC)

isolation. Livers were perfused with pre-warmed PBS (42 °C) at 5 mL/min, then

switched to enzyme buffer solution (EBS, 15 mL) containing liberase (0.05 mg/mL)

(Sigma-Aldrich, #5401127001). For zonated hepatocyte isolation, 833 µL of 5-10mM

digitonin (Sigma-Aldrich, #D141-500MG) was injected via the unconnected catheter

(IVC for PP, PV for PC), after which the vessel was cut, and perfusion was immediately

resumed. Following perfusion, the liver was cut from the mouse and placed in cold

DMEM (without glucose) or Krebs-Henseleit (KH) buffer, gently dissociated, and filtered

through a 100 µm cell strainer. For liver hepatocyte purification, the cells were

centrifuged at 40 x g for 5 min at 4 °C, followed by Percoll (Sigma-Aldrich, #P4937-

500ML) solution (80 x g for 10 min at 4 °C), then washed by DMEM or KH buffer.

Hepatocytes were counted and assessed for viability prior to downstream applications.

ChIP sequencing

Fixation: Total hepatocyte (Fig. 1 and Fig. S1) and periportal/pericentral hepatocyte

(Fig. S2) isolation was performed on fasted and fed mice as described above with the

exception that all sample processing after liberase digestion was done using ice-cold

DBPS without calcium or magnesium (Gibco, #14190136) containing protease (Sigma,

#S8830) and phosphatase inhibitors (Sigma, #P5726) (referred to as DPBS buffer).

After final wash (see above), hepatocytes were resuspended in room temperature

DPBS buffer at concentration of 1 million cells/mL and formaldehyde (ThermoFisher,

#28908) was added to final concentration of 1%. Hepatocyte suspension was fixed at

room temperature for 10 min with gentle rolling. Fixation was stopped by adding glycine

in water (final concentration of 125 mM) containing protease and phosphatase

inhibitors, and hepatocytes were incubated for additional 15 min at room temperature

with gentle rolling. Hepatocytes were washed 1X in ice-cold DPBPS buffer, aliquoted in

Eppendorf tubes at 1 million cells per tube, pelleted/aspirated, and snap frozen in liquid

nitrogen for long-term storage at -80°C.

<u>Immunoprecipitation</u>: Immunoprecipitation reagents was prepared by washing Protein A

Dynabeads (ThermoFisher, #10002D) in chromatin dilution buffer (0.5% Triton X-100,

2mM EDTA, 20mM Tris, 150 mM NaCl in water) on DynaMag-2 (ThermoFisher,

#12321D) and combining with anti RNAPII subunit B1 (Rpb1) NTD rabbit monoclonal

antibody (Cell Signaling, #14958) at ratio of 630 µg Dynabeads to 4 µg antibody per IP

reaction. Dynabead-antibody mixture was pre-incubated at 4°C for 3 hours with gentle

rolling.

<u>Sonication</u>: Fixed-frozen hepatocyte pellets (1 million cells per IP reaction) were thawed

on ice and washed 1X with 500 µL cold DPBS buffer before resuspension in 500 µL

cold DPBS buffer with 0.5% Triton-X100 and incubation on ice for 10 min. Hepatocytes

were then centrifuged at 2600 xg for 5 min at 4°C, gently aspirated, and washed 1X with

500 µL cold tris-EDTA buffer (Sigma, #93283) containing 0.5% SDS (Sigma, #71736)

with protease/phosphatase inhibitors (TE-SDS buffer) before centrifuging again at 2600

xg for 5 min at 4°C. Supernatant was carefully aspirated, pellet was resuspended with

200 µL cold TE-SDS buffer, and sample was transferred to 1.5 mL Bioruptor Pico tubes

(Diagenode, #C30010016) on ice before sonication in 4°C water bath for 3 cycles (30

sec on / 30 sec off) with Easy Mode using Bioruptor Pico sonication device (Diagenode,

#B01080010). After sonication, sample was transferred back to 1.5 mL Eppendorf tubes

on ice and combined with 800 µL cold chromatin dilution buffer with

protease/phosphatase inhibitors (see above). Samples were centrifuged at 16,000 xg

for for 20 min at 4°C to remove debris and supernatant containing soluble chromatin

was transferred to new Eppendorf tubes on ice. DNA concentration across all samples

was checked using Qubit dsDNA HS kit (ThermoFisher, #Q33231) and normalized with

chromatin dilution buffer. For each sample, a 200 µL aliquot was collected as input and

a second aliquot (900 µL) was combined with 100 µL of Dynabead-antibody mixture,

briefly vortexed, and incubated overnight at 4°C with gentle rolling.

Washing: After overnight incubation, IP samples were washed in 4°C cold-room as

follows. Samples were placed on DynaMag-2 for 1 min, supernatant was removed and

discarded, 500 µL of pre-chilled wash buffer was added, and samples were rotated end-

over-end in cold-room for 5 min before repeating this process. Washes consisted of first

RIPA-140 (0.1% SDS, 1% Triton X-100, 1 mM EDTA, 10 mM Tris, 140 mM NaCl, 0.1%

sodium deoxycholate (Sigma, #D6750) in water), second RIPA-300 (0.1% SDS, 1%

Triton X-100, 1 mM EDTA, 10 mM Tris, 300 mM NaCl, 0.1% sodium deoxycholate in

water), third LiCl buffer (250 mM LiCl (Fisher Scientific, #L121), 0.5% Igepal ca-630 (MP

Biomedicals, # 198596), 1 mM EDTA, 10 mM Tris, 0.5% sodium deoxycholate in water),

fourth Tris-EDTA buffer (Sigma, #93283) with 0.2% Triton X-100, and fifth Tris-EDTA

buffer alone.

Elution: Wash buffer was removed, and chromatin was eluted from Dynabeads as

follows[37]. Briefly, 100 µL of elution buffer (1% SDS, 1 mM EDTA, 10 mM Tris in water)

was added to beads before vortexing and incubating at 65°C for 5 min followed by room

temperature incubation for 15min with vortexing every 5 min. Beads were placed on

DynaMag-2 for 1 min, and supernatant containing immunoprecipitated chromatin (~100

µL) was carefully collected and saved. Beads then underwent a second round of elution,

and the two supernatant collections were combined (~200 µL total).

<u>RNase digestion, reverse cross-linking, and DNA purification</u>: Input and IP samples

were combined with NaCl (final concentration of 160 mM) and RNase A (final

concentration of 20 µG/mL) (Roche, # 11119915001) and incubated at 65°C overnight

as previously outlined[37]. Afterwards, EDTA (final concentration of 5 mM) and proteinase

K (final concentration 200 µG/mL) (Invitrogen, # 100005393) were added, and samples

were incubated at 45°C for 2 h. Finally, input and IP DNA was purified using ChIP DNA

Clean & Concentrator kit (Zymo Research, #D5205) according to manufacturer's

guidelines, and DNA concentration was quantified using Qubit dsDNA HS kit. Fraction

of purified input DNA was run on agarose gel to assess fragmentation pattern (~100-

500 bp).

<u>Library preparation, sequencing, and data processing:</u> Library preparation was

performed using NEBNext® Ultra™ II DNA Library Prep Kit for Illumina® (New England

Biolabs, #E7645) according to manufacturer's guidelines with NEBNext® Multiplex

Oligos for Illumina® single Index Primers Set 1 and Set 2 (New England Biolabs,

#E7335 and #E7500). Premade libraries were sent to Novogene for sequencing using

NovaSeq paired-end sequencing at 150 base pairs per read (PE150). Raw fastq files

were first processed to remove adapter sequences and low-quality bases using Trim

Galore (v0.6.7) with "--stringency 5". Trimmed reads were then aligned to mm10

reference genome using bowtie2 (v2.4.5) with default parameters[34]. The resulting SAM

files were converted to BAM files using samtools (v1.6) view with "-f 2 -q 10"[35].

Duplicates were removed using samtools rmdup. Coverage tracks were generated

using the bamCoverage tool from the deepTools (v3.5.1) suite with the "--extendReads -

-normalizeUsing CPM" option[36]. Input normalization was performed using log2 ratio and

bin size set to 5 with bigwigCompare from deepTools. Normalized BigWig files were

visualized using Integrative Genomics Viewer (IGV)[38]. Total hepatocyte gene tracks

(Fig. 1 and Fig. S1) represent IP over input signal; periportal/pericentral hepatocyte

gene tracks (Fig. S2) represent IP signal alone since input signal was negligible in

previous experiments.

RNA isolation and quantitative PCR (RT-qPCR)

Total RNA isolation from isolated hepatocytes was done using the RNeasy mini kit

(Qiagen, #74106) in combination with TRIzol (Invitrogen, #15596026) according to the

manufacture's protocol. cDNA was synthesized using SuperScript IV VILO (Invitrogen,

#11756050) and RT-qPCR was performed using PowerUp SYBR Green Master Mix

(Applied Biosystems, #A25778) on a QuantStudio 6 system (Applied Biosystems).

Relative gene expression was determined by the ΔΔCt method and normalized to *Ppib*.

Primer sequences are listed in Table S2.

Targeted Single-cell RNA sequencing (targeted scRNA-seq)

To characterize dual-modal hepatocytes, we analyzed a publicly available targeted

single-cell RNA sequencing (scRNA-seq) dataset covering 61 specific genes[5]. The

panel consisted of pericentral and periportal hepatocyte markers, general parenchymal

and non-parenchymal cell markers, as well as genes involved in gluconeogenesis,

lipogenesis, bile acid synthesis, and several secreted hepatokines. Raw FASTQ files

were obtained from the NCBI Gene Expression Omnibus (GEO; accession no.

GSE263419). Gene expression levels were quantified using Cell Ranger (v.6.0.1; 10x

Genomics) in targeted gene expression mode. Positive cells were defined by applying

thresholds determined via ridge plot analysis and compared with RT-qPCR results as

previously described[5].

HCR RNA-FISH

Livers were fixed in 4% paraformaldehyde (PFA) for 3 hours, cryoprotected in PFA + 30

% sucrose for overnight, embedded in OCT, and tissue blocks were kept at -80 °C until

sectioning. After sectioned at 8-10 μm thickness, the sections were post-fixed,

permeabilized with ethanol, and treated with proteinase K prior to hybridization as

previously described[5]. HCR RNA-FISH probes (Molecular Instruments) targeting *Pck1*

(B3), *Fasn* (B1), and *Glul* (B2) were hybridized overnight at 37 °C (0.4 pmol of each

probe set/100 uL). Once excess probes were removed, the amplification stage was

performed according to the manufacture's protocol for 12 hours (B3=546, B1=647,

B2=488, 6 pmol each of hairpin/100 uL)[39]. Sections were then washed, counterstained

with DAPI, and mounted with antifade medium. Images were acquired on an upright,

wide-field Olympus BX- 63 Microscope equipped with a Super Apochromatic objective

lens (60×/1.35 N.A., Pixel size (x,y) = 107.5 nm, z-step = 300nm). MetaMorph software

(Molecular Devices, v7.10.1.161) was used for controlling microscope automation and

image acquisition. Pericentral hepatocytes were identified by *Glul* expression, and

periportal hepatocytes were identified by the bile duct-associated morphology. Liver

lobule images were taken by taking sequential images and processed on FIJI (v2.16.0).

Transcription site analysis in hepatic lobules was performed using SmallFish (v2.1.10),

a python implementation of FishQuant[40]. Cell segmentation was performed in 2D using

Cellpose (https://github.com/MouseLand/cellpose); and spot detection was performed

via big-fish package (https://github.com/fish-quant/big-fish).

Stable isotope tracing analyses

For pyruvate-to glucose tracing experiments, isolated hepatocytes (1×10^5 cells) were incubated in KH buffer containing 1 mM [2,3-$^{13}C_2$] sodium pyruvate or unlabeled pyruvate, 1 mM sodium lactate, 2 mM L-glutamine, and 1 mM BSA-conjugated palmitic acid at 37 °C for 1 hour. 200 μL of the media was extracted with methanol containing 2-deoxyglucose, centrifuged ($13,100 \times g$, 10 min, 4 °C), and the supernatant was dried under gentle nitrogen flow. Samples were then reacted with hydroxylanmine followed by acetic anhydride as previously described[5]. After reconstitution in ethyl acetate, the samples were analyzed by gas chromatography mass spectrometry (GC (7890)-MS (5975C), Agilent) in chemical ionization (CI) mode using methane as the CI gas. Mass isotopologue distributions were analyzed using MassHunter software (Agilent) and corrected for natural isotope abundance. Glucose isotopologues are reported as molar fractions (M0–M6). The sum of all isotopologues of the molecules, m_i (where i = 1 to 6), is equal to 1 or 100%. The labelled isotopologue fractions consist of a distribution not affected by the dilution with unlabeled compounds, reported as $m_i/\Sigma m_i$, in percent. The enrichment ΣM_n is the weighted sum of the labelled species ($\Sigma M_n = 1*M_1 + 2*M_2 + 3*M_3 + 4*M_4 + 5*M_5 + 6*M_6$) = average number of ^{13}C carbons/molecule as previously reported[5].

For *in vivo* deuterium labeling, mice were subjected to time-restricted feeding as described above. For fed conditions, mice received an intraperitoneal (IP) injection of 0.9% NaCl in deuterated water (30 μL/g body weight) at 07:00, after which drinking water was replaced with 6% ^2H_2O. Chow and 6 % ^2H_2O with 20 % sucrose (w/v) were provided at 09:00, and mice were sacrificed at 13:00. For fasted conditions, mice were

fed chow and sucrose water (without ^2H_2O) from 09:00 to 13:00, fasted for 24 h, injected

with ^2H_2O and regular drinking water was replaced with 6 % ^2H_2O water at 07:00 the

following day, and sacrificed at 13:00. Lipids were extracted from isolated hepatocytes

(1x10^6 cells) following alkaline saponification in 1 M NaOH in 70 % ethanol in water with

heptadecanoic acid (C17:0) as an internal standard. Extracted fatty acids were

derivatized with BSTFA and analyzed by GC-MS (Agilent) with a DB-5MS column.

Palmitate deuterium enrichment was quantified from the m/z 313 fragment and

calculated. The total labeled fraction of palmitate was calculated with fraction

enrichment. The total palmitate was calculated relative to the concentration of

heptadecanoic acid. The newly synthesized palmitate was calculated with the function:

Newly synthesized palmitate = Total palmitate * total fraction of labeled

palmitate/deuterium enrichment in plasma/tissue weight.

^{18}O water labeling in vivo

Mice were subjected to time-restricted feeding as described above. In both fed and

fasted conditions, the mice were gavage with ^{18}O water or regular water at 12:48,

received IP injection of ^{18}O water or regular water at 12:53, then sacrificed at 13:00. The

liver was rinsed with 150 mM ammonium acetate before frozen in pre-chilled

isopentane. A 20 um thickness of tissue section was used for DESI imaging. The slide

was analyzed with a Waters Cyclic Ion Mobility-Mass Spectrometry (Cyclic-iMS).

The slide was placed in desiccator for about half an hour before loading into DESI

stage. The solvent was methanol:water=60:40(v:v) with 200ng/mL LeuEnk. The flow

rate was set to 2 μL/min. The resolution was set to 60um with 300 μm/sec. The mass

range was set to 50 – 1200 m/z, and the mobility was set to 1 pass with TW ramp of

TOF settings are 16 – 28 V/ms.

DESI and MALDI metabolic spatial imaging

Mice were subjected to time-restricted feeding as described above. On the day of the

experiment, mice were provided with D17011901px (Modified OSD with Macronutrient

Content Similar to LabDiet 5053) with $^{13}C_6$ glucose or unlabeled glucose (for 1 g of

premix, 1.31 g of glucose was added) at 9:00. Mice were then sacrificed at 13:00,

corresponding to 4 hours of feeding, and the liver was frozen in pre-chilled isopentane.

For DESI analysis, the slices were sectioned into 20um thickness. The ^{13}C samples was

analyzed with DESI-Xevo TQ absolute MS (Waters). The solvent was

methanol:water=80:20(v:v) with 200ng/mL LeuEnk with a flow rate of 1.2ul/mL and was

scanned with 25 x 25 um spatial resolution. The metabolites and their isotopolgues was

analyzed in the negative multiple reaction monitoring (MRM) mode. The data was

processed with HDI software (Waters).

PrimeFlow

After isolating hepatocytes as described above, the hepatocytes went through the

PrimeFlow (Invitrogen, #88-18005-204) protocol based on the manufacturer's

instructions with minor modifications. Briefly, hepatocytes were fixed using PrimeFlow

RNA Fixation Buffers. Cells were then permeabilized in PrimeFlow RNA

Permeabilization Buffer supplemented with RNase inhibitors, followed by a second

fixation step. After washing, cells were hybridized with target-specific RNA probe sets

diluted in PrimeFlow RNA Target Probe Diluent for 2 hours at 40 °C. Samples were

washed in PrimeFlow RNA Wash Buffer containing RNase inhibitor and stored

overnight at 2-8 °C in the dark. On the following day, signal amplification was performed

through sequential incubations with PreAmp Mix, Amp Mix, and fluorescently labeled

probes, each at 40 °C, with intervening washes according to the manufacturer's

instructions. Following the final labeling step, cells were washed, resuspended in

PrimeFlow RNA Storage Buffer and analyzed on BD FACSAria III. All centrifugation

steps were done at 800 × g unless otherwise specified.

Hyperinsulinemic-euglycemic clamp experiments

Hyperinsulinemic-euglycemic clamp studies were performed in conscious, unrestrained

mice. Briefly, mice were surgically implanted with catheters in the jugular vein for

infusions and the carotid artery for blood sampling. After recovering for at least 3 days

following surgery, the mice were subjected to time-restricted feeding as described

above. On the day of the experiment, catheters were connected to infusion lines, and

basal blood glucose was measured from the arterial blood using a glucometer.

Continuous insulin was infused at the indicated rates and maintained for 2 hours. Blood

glucose was clamped at 150 mg/dL by a variable infusion of 20% glucose solution,

adjusted based on blood glucose measurements every 10-20 minutes. At the end of the

clamp, liver perfusion for total hepatocyte isolation was performed.

Spatial Transcriptomics

For high-fat diet studies, fresh frozen mouse livers were embedded in Neg-50 and

stored at -80 °C until sectioning. After sectioned at 10 μm thickness, **s**ections were

adhered to capture areas by brief warming onto Visium v1 slides (10x Genomics). For

humanized liver studies, livers were fixed in 4% paraformaldehyde (PFA) for 3 hours,

cryoprotected in PFA + 30 % sucrose for overnight, embedded in OCT, and tissue

blocks were kept at -80 °C until sectioning. After sectioned at 10 μm thickness, Visium

v2 (prepared with CytAssist) was performed using the CytAssist instrument. For both

studies, the sample preparation was performed according to the manufacturer's

guidelines. Briefly, tissue sections were stained with hematoxylin and eosin (H&E),

imaged using a brightfield microscope for histological reference and spatial registration.

RNA capture, reverse transcription, second-strand synthesis, cDNA amplification, and

library construction were performed. Libraries were indexed, quality-controlled, and

sequenced on an Illumina platform using paired-end sequencing. Raw sequencing data

were processed using Space Ranger (v2.0.0 for high-fat diet studies with reference

genome: mm10-2020-A, v3.1.0 for humanized liver studies with reference genome:

GRCh38-2020-A, 10x Genomics) to align reads to the reference genome and generate

spatial gene expression matrices. Spatial alignment was performed using H&E images,

and downstream analyses were conducted using standard single-cell and spatial

transcriptomics workflows.

QUANTIFICATION AND STATISTICAL ANALYSIS

Excel (v16.101.3), Prism (v10.6.1) GraphPad Software, were used for data processing,

analyses, and graph productions in the experiments. All data are presented as the

mean +/- standard deviation unless otherwise noted. Student's t-test with unpaired two-

tailed p values of *$p<0.05$, **$p<0.01$, and ***$p<0.001$ was considered statistically

significant when comparing two groups. (N.S.=not statistically significant).

Figures/Images were created by Powerpoint (v16.101.3), IGV (v2.19.7), Loupe Browser

(v9.0.0), FIJI (v2.16.0), QuPath (v0.6.0) and Adobe Illustrator (v28.1).

REFERENCES

Ben-Moshe, S. & Itzkovitz, S. Spatial heterogeneity in the mammalian liver. *Nat Rev Gastroenterol Hepatol* **16**, 395-410 (2019). https://doi.org:10.1038/s41575-019-0134-x

Martini, T., Naef, F. & Tchorz, J. S. Spatiotemporal Metabolic Liver Zonation and Consequences on Pathophysiology. *Annu Rev Pathol* **18**, 439-466 (2023). https://doi.org:10.1146/annurev-pathmechdis-031521-024831

Halpern, K. B. *et al.* Single-cell spatial reconstruction reveals global division of labour in the mammalian liver. *Nature* **542**, 352-356 (2017). https://doi.org:10.1038/nature21065

Rosenberger, F. A. *et al.* Spatial single-cell mass spectrometry defines zonation of the hepatocyte proteome. *Nat Methods* **20**, 1530-1536 (2023). https://doi.org:10.1038/s41592-023-02007-6

Okada, J. *et al.* Spatial hepatocyte plasticity of gluconeogenesis during the metabolic transitions between fed, fasted and starvation states. *Nat Metab* **7**, 1073-1091 (2025). https://doi.org:10.1038/s42255-025-01269-y

Sasse, D., Katz, N. & Jungermann, K. Functional heterogeneity of rat liver parenchyma and of isolated hepatocytes. *FEBS Lett* **57**, 83-88 (1975). https://doi.org:10.1016/0014-5793(75)80157-8

Wagle, S. R., Ingebretsen, W. R. & Sampson, L. Studies on gluconeogenesis and stimulation of glycogen and protein synthesis in isolated hepatocytes in alloxan diabetic, normal fed and fasted animals. *Acta Diabetol Lat* **12**, 185-198 (1975). https://doi.org:10.1007/BF02581299

Bartels, H., Vogt, B. & Jungermann, K. Glycogen synthesis via the indirect gluconeogenic pathway in the periportal and via the direct glucose utilizing pathway in the perivenous zone of perfused rat liver. *Histochemistry* **89**, 253-260 (1988). https://doi.org:10.1007/BF00493149

Petersen, M. C., Vatner, D. F. & Shulman, G. I. Regulation of hepatic glucose metabolism in health and disease. *Nat Rev Endocrinol* **13**, 572-587 (2017). https://doi.org:10.1038/nrendo.2017.80

Coelho, M. *et al.* Enrichment of hepatic glycogen and plasma glucose from $H(2)(18)O$ informs gluconeogenic and indirect pathway fluxes in naturally feeding mice. *NMR Biomed* **36**, e4837 (2023). https://doi.org:10.1002/nbm.4837

Adeva-Andany, M. M., Gonzalez-Lucan, M., Donapetry-Garcia, C., Fernandez-Fernandez, C. & Ameneiros-Rodriguez, E. Glycogen metabolism in humans. *BBA Clin* **5**, 85-100 (2016). https://doi.org:10.1016/j.bbacli.2016.02.001

Youn, D. Y. *et al.* The Mediator complex kinase module is necessary for fructose regulation of liver glycogen levels through induction of glucose-6-phosphatase catalytic subunit (G6pc). *Mol Metab* **48**, 101227 (2021). https://doi.org:10.1016/j.molmet.2021.101227

Core, L. & Adelman, K. Promoter-proximal pausing of RNA polymerase II: a nexus of gene regulation. *Genes Dev* **33**, 960-982 (2019). https://doi.org:10.1101/gad.325142.119

14   Chen, K. S. & Katz, J. Zonation of glycogen and glucose syntheses, but not
glycolysis, in rat liver. *Biochem J* **255**, 99-104 (1988).
https://doi.org:10.1042/bj2550099
15   Quistorff, B. Gluconeogenesis in periportal and perivenous hepatocytes of rat
liver, isolated by a new high-yield digitonin/collagenase perfusion technique.
Biochem J **229**, 221-226 (1985). https://doi.org:10.1042/bj2290221
16   Droin, C. *et al.* Space-time logic of liver gene expression at sub-lobular scale. *Nat*
Metab **3**, 43-58 (2021). https://doi.org:10.1038/s42255-020-00323-1
17   Henning, A. L., Sampson, J. N. B. & McFarlin, B. K. Measurement of Low-
Abundance Intracellular mRNA Using Amplified FISH Staining and Image-Based
Flow Cytometry. *Curr Protoc Cytom* **76**, 7 46 41-47 46 48 (2016).
https://doi.org:10.1002/0471142956.cy0746s76
18   Zeleznikar, R. J. & Goldberg, N. D. Kinetics and compartmentation of energy
metabolism in intact skeletal muscle determined from 18O labeling of metabolite
phosphoryls. *J Biol Chem* **266**, 15110-15119 (1991).
19   Goldberg, N. D., Ames, A. A., 3rd, Gander, J. E. & Walseth, T. F. Magnitude of
increase in retinal cGMP metabolic flux determined by 18O incorporation into
nucleotide alpha-phosphoryls corresponds with intensity of photic stimulation. *J*
Biol Chem **258**, 9213-9219 (1983).
20   Walseth, T. F., Gander, J. E., Eide, S. J., Krick, T. P. & Goldberg, N. D. 18O
labeling of adenine nucleotide alpha-phosphoryls in platelets. Contribution by
phosphodiesterase-catalyzed hydrolysis of cAMP. *J Biol Chem* **258**, 1544-1558
(1983).
21   Dawis, S. M. *et al.* Adenosine triphosphate utilization rates and metabolic pool
sizes in intact cells measured by transfer of 18O from water. *Biophys J* **55**, 79-99
(1989). https://doi.org:10.1016/S0006-3495(89)82782-1
22   Zeleznikar, R. J. *et al.* Evidence for compartmentalized adenylate kinase
catalysis serving a high energy phosphoryl transfer function in rat skeletal
muscle. *J Biol Chem* **265**, 300-311 (1990).
23   Tang, Y. *et al.* TIGAR deficiency enhances skeletal muscle thermogenesis by
increasing neuromuscular junction cholinergic signaling. *Elife* **11** (2022).
https://doi.org:10.7554/eLife.73360
24   Hall, A. *et al.* Transaminase abnormalities and adaptations of the liver lobule
manifest at specific cut-offs of steatosis. *Sci Rep* **7**, 40977 (2017).
https://doi.org:10.1038/srep40977
25   Sugahara, G., Ishida, Y., Sun, J., Tateno, C. & Saito, T. Art of Making Artificial
Liver: Depicting Human Liver Biology and Diseases in Mice. *Semin Liver Dis* **40**,
189-212 (2020). https://doi.org:10.1055/s-0040-1701444
26   Seubnooch, P. *et al.* Characterisation of hepatic lipid signature distributed across
the liver zonation using mass spectrometry imaging. *JHEP Rep* **5**, 100725
(2023). https://doi.org:10.1016/j.jhepr.2023.100725
27   Hatting, M., Tavares, C. D. J., Sharabi, K., Rines, A. K. & Puigserver, P. Insulin
regulation of gluconeogenesis. *Ann N Y Acad Sci* **1411**, 21-35 (2018).
https://doi.org:10.1111/nyas.13435

28 Sahoo, B., Srivastava, M., Katiyar, A., Ecelbarger, C. & Tiwari, S. Liver or kidney:
Who has the oar in the gluconeogenesis boat and when? *World J Diabetes* **14**,
1049-1056 (2023). https://doi.org:10.4239/wjd.v14.i7.1049
29 Mutel, E. *et al.* Control of blood glucose in the absence of hepatic glucose
production during prolonged fasting in mice: induction of renal and intestinal
gluconeogenesis by glucagon. *Diabetes* **60**, 3121-3131 (2011).
https://doi.org:10.2337/db11-0571
30 Edgerton, D. S. *et al.* Insulin's direct hepatic effect explains the inhibition of
glucose production caused by insulin secretion. *JCI Insight* **2**, e91863 (2017).
https://doi.org:10.1172/jci.insight.91863
31 Buettner, C. *et al.* Severe impairment in liver insulin signaling fails to alter hepatic
insulin action in conscious mice. *J Clin Invest* **115**, 1306-1313 (2005).
https://doi.org:10.1172/JCI23109
32 Tosh, D., Alberti, G. M. & Agius, L. Glucagon regulation of gluconeogenesis and
ketogenesis in periportal and perivenous rat hepatocytes. Heterogeneity of
hormone action and of the mitochondrial redox state. *Biochem J* **256**, 197-204
(1988). https://doi.org:10.1042/bj2560197
33 Buglakova, E. *et al.* Spatial single-cell isotope tracing reveals heterogeneity of de
novo fatty acid synthesis in cancer. *Nat Metab* **6**, 1695-1711 (2024).
https://doi.org:10.1038/s42255-024-01118-4
34 Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat*
Methods **9**, 357-359 (2012). https://doi.org:10.1038/nmeth.1923
35 Li, H. A statistical framework for SNP calling, mutation discovery, association
mapping and population genetical parameter estimation from sequencing data.
Bioinformatics **27**, 2987-2993 (2011).
https://doi.org:10.1093/bioinformatics/btr509
36 Ramirez, F. *et al.* deepTools2: a next generation web server for deep-sequencing
data analysis. *Nucleic Acids Res* **44**, W160-165 (2016).
https://doi.org:10.1093/nar/gkw257
37 Sullivan, A. E. & Santos, S. D. M. An Optimized Protocol for ChIP-Seq from
Human Embryonic Stem Cell Cultures. *STAR Protoc* **1**, 100062 (2020).
https://doi.org:10.1016/j.xpro.2020.100062
38 Robinson, J. T. *et al.* Integrative genomics viewer. *Nat Biotechnol* **29**, 24-26
(2011). https://doi.org:10.1038/nbt.1754
39 Choi, H. M. *et al.* Programmable in situ amplification for multiplexed imaging of
mRNA expression. *Nat Biotechnol* **28**, 1208-1212 (2010).
https://doi.org:10.1038/nbt.1692
40 Imbert, A. *et al.* FISH-quant v2: a scalable and modular tool for smFISH image
analysis. *RNA* **28**, 786-795 (2022). https://doi.org:10.1261/rna.079073.121
1116

Figure 1 – *Pck1* is transcribed in hepatocytes the fed state

(A) *Fasn*

(B) *Pck1*

(C) *Alb*

(D) *Fasn*

(E) *Pck1*

(F) *Alb*

(G) *Ins1*

Fed   Fast

Figure 2 – *Fasn* and *Pck1* are co-expressed in a subset of periportal hepatocytes

(A) Fed, Fast

(B) Pericentral, Periportal

(C) Pericentral Markers — *Cyp2e1*, *Gulo*

(D) Periportal Markers — *Cyp2f2*, *Hsd17b13*

(E) *Fasn+* hepatocytes

(F) *Pck1+* hepatocytes

(G) Dual-positive hepatocytes

Figure 3 – *Fasn* and *Pck1* are actively co-transcribed in a subset of periportal hepatocytes

Figure 4 – Periportal hepatocytes have basal pyruvate-to-glucose flux in the fed state

Figure 5 – A subset of liver regions has higher ATP turnover in the fed state

(A) AMP (M0) 346.0543 m/z

Fed   Fast

Min (0)   Max (2000)

Unlabeled   18O-Labeled   Unlabeled   18O-Labeled

(B) AMP (M0+2) 348.0586 m/z

Fed   Fast

Min (0)   Max (200)

Unlabeled   18O-Labeled   Unlabeled   18O-Labeled

(C) ADP (M0+2) 428.0248 m/z   ATP-Na (M0+2) 529.9580 m/z

Fed   Fast   Fed   Fast

Min (0)   Max (100)   Min (0)   Max (40)

(D)

Fed 18O-Labeled

Min (0)   Max (40) | 50C_95_600   (X:66.22000 Y:27.35420 Scan:175941) : 0.00
Min (0)   Max (150) | 50C_95_600   (X:66.22000 Y:27.35420 Scan:175941) : 0.00
Min (0)   Max (150) | 50C_95_600   (X:66.22000 Y:27.35420 Scan:175941) : 0.00

- 🟥 AMP (M0+2) 348.0586 m/z
- 🟩 ADP (M0+2) 428.0248 m/z
- 🟦 ATP+Na (M0+2) 529.9580 m/z
- ⬜ High AMP/ADP/ATP turnover

Figure 6 – A subset of hepatocytes is lipogenic and gluconeogenic

(A)

U13C Glucose

m0+3

m0+6

Glucose-6-phosphate

Gluconeogenesis

Glycolysis

Phosphoenolpyruvate

Pyruvate

Acetyl-CoA

Oxaloacetate → Citrate

De novo lipogenesis

TCA cycle

Palmitic acid

m0+2

m0+4

■ m0+4 Palmitic acid (C16) (*de novo* lipogenesis)

■ m0+3 Glucose-6-phosphate (gluconeogenesis)

■ Dual-modal spots

(B) U13C glucose labeled (DESI 25 x 25 μm)

U13C glucose labeled (DESI 25 x 25 μm)

50 μm

Min (35000) Max (70000)
Min (15000) Max (30000)

(C) U13C glucose labeled (MALDI 50 x 50 μm)

unlabeled glucose control (MALDI 50 x 50 μm)

3 mm

(E)

(D) U13C glucose labeled (MALDI 50 x 50 μm)

300 μm

161%
31% 100%
242%
21% 100%

(F) U13C glucose labeled (MALDI 10 x 10 μm)

10 μm

Figure 7 – Dual-positive spots increase in high-fat diet fed-mice liver

Supplementary Figures

Figure S1 – *G6pc* is transcribed in hepatocytes in the fed state

(A)

Acly

(B)

Elovl6

(C)

G6pc

Fed

Fast

Figure S2 – *Pck1* is transcribed in periportal hepatocytes in the fed state

Figure S3 – Acly, Acaca, Elovl6, and G6pc are co-expressed in a subset of hepatocytes

(A) *Acly+* hepatocytes

(B) *Acaca+* hepatocytes

(C) *Elovl6+* hepatocytes

(D) *G6pc+* hepatocytes

(E) *Acly/Acaca/Elovl6/G6pc* positive hepatocytes

Figure S4 – *Pck1* is actively transcribed in the fed state

Figure S5 – Dual-positive hepatocytes are insulin resistant in suppression of *Pck1*

Figure S6 – Humanized mouse liver has dual-positive spots

Figure S7 – t-SNE separates NCD and 3MHFD

(A) NCD / 3MHFD — t-SNE1 / t-SNE2

(B) NCD / 3MHFD

(C) t-SNE1 / t-SNE2

(D) Pericentral Markers — *Cyp2e1* / *Glul*

(E) Periportal Markers — *Cyp2f2* / *Hsd17b13*

(F) Pericentral / Periportal

(G) *Fasn* Positive spots — NCD / 3MHFD

(H) *Pck1* Positive spots — NCD / 3MHFD

Table S1 – Compendium of $^{18}O/^{16}O$ exchange reactions which determine ATP turnover

Reaction:	Parameters:
$\gamma ATP + [^{18}O] \cdot H_2O \longrightarrow [^{18}O] \cdot P_i + ADP$	ATP hydrolysis
$[^{18}O] \cdot P_i + ADP \longrightarrow [^{18}O] \cdot \gamma ATP$	ATP synthesis
$[^{18}O] \cdot \gamma ATP + Cr \longrightarrow [^{18}O] \cdot CrP + ADP$	CK-catalyzed phosphotransfer
$[^{18}O] \cdot \gamma ATP + AMP \longrightarrow [^{18}O] \cdot \beta ADP + ADP \longrightarrow [^{18}O] \cdot \beta ATP + AMP$	AK-catalyzed phosphotransfer

ATP turnover reflects the percentage of ^{16}O in ATP replaced by ^{18}O in the aliquot of cells analyzed, reflecting whole cell energetics. CK=creatine kinase, AK=adenylate kinase

Table S2 – Primer Sequences

Gene	Sequence (5' - 3')
Fasn _FWD (Mouse)	GGTCGTTTCTCCATTAAATTCTCAT
Fasn _REV (Mouse)	CTAGAAACTTTCCCAGAAATCTTCC
Pck1 _FWD (Mouse)	TCTCTGATCCAGACCTTCCAA
Pck1 _REV (Mouse)	GAAGTCCAGACCGTTATGCAG
Alb _FWD (Mouse)	CAAAGACGTGTGTTGCCGAT
Alb _REV (Mouse)	ACGGAGGTTTGGAATGGCAC
Cyp2e1 _FWD (Mouse)	CACAGCCAAGAACCCATGTACA
Cyp2e1 _REV (Mouse)	CAGGAGCCCATATCTCAGAGTTG
Cyp2f2 _FWD (Mouse)	CCTTTGACCCCGTGTTTATCC
Cyp2f2 _REV (Mouse)	TCGAAGCGACTTCCGAAGAC
Ppib _FWD (Mouse)	CAAGCATGTGGTTTTCGGCA
Ppib _REV (Mouse)	GCTGTCTGTCTTGGTGCTCT
Fasn _FWD (Human)	TTCTACGGCTCCACGCTCTTCC
Fasn _REV (Human)	GAAGAGTCTTCGTCAGCCAGGA
Pck1 _FWD (Human)	CATTGCCTGGATGAAGTTTGACG
Pck1 _REV (Human)	GGGTTGGTCTTCACTGAAGTCC
Ppib _FWD (Human)	AACGCAGGCAAAGACACCAACG
Ppib _REV (Human)	TCTGTCTTGGTGCTCTCCACCT